Navigation Links
StemCyte, Inc. Reaches 1,000th Cord Blood Stem Cell Shipment for Transplant Milestone

COVINA, Calif., May 28 /PRNewswire/ -- StemCyte, Inc., a privately held cord blood bank and stem cell therapeutics company, recently released their 1,000th cord blood stem cell shipment for transplant. This marks another landmark in the company's rapid growth as one of the world's leading providers of quality, prescription cord blood stem cell product.

(Photo: )

StemCyte will announce this major milestone at the 7th Annual International Umbilical Cord Blood Transplantation Symposium in Los Angeles June 5-6, 2009.

"When StemCyte was founded in 1997, there were not even 1,000 cumulative cord blood transplants worldwide. I am especially proud of the progress we have made during this time," says Dr. Robert Chow, StemCyte Founder.

StemCyte has now provided prescription cord blood product to over 180 transplant centers worldwide in five continents and is a trusted name among transplant physicians. With both public and private banks in the U.S., India and Taiwan, StemCyte has emerged as a global leader in cord blood banking.

Cord blood stem cells have become a viable option to treat a variety of illnesses including leukemia, lymphomas, Autoimmune diseases and Genetic Blood disorders such as Thalassemia sickle-cell disease.

"With over 20 years of human safety and efficacy data, umbilical cord blood stem cells are emerging as a prime source of stem cells for the field of regenerative medicine, which is the repair of injured tissues, nerves and organs. Research and clinical studies are increasing at an incredible pace and this will result in the treatment of some of the most devastating diseases. StemCyte's large library of HLA typed product as well as our experience and expertise in this field will position us very well to take advantage of these emerging therapies," explains StemCyte's CEO Ken Giacin.

In 2008, StemCyte, Inc. signed two research and licensing agreements for human umbilical cord blood stem cell treatment for spinal cord injury, stroke, multiple sclerosis, Alzheimer's disease, Parkinson's disease, ALS, and other problems of the central nervous system. The initiatives are being developed by Professor Wise Young M.D., Ph.D. at Rutgers the State University, New Jersey and Professor John Lin M.D., Ph.D. at China Medical University Hospital, Taiwan.

About StemCyte

StemCyte, Inc. is a global leader in stem cell therapeutics with a marketed umbilical cord blood stem cell transplantation product. The company's proprietary plasma-depleted cord blood stem cell products have been used to cure hundreds of patients with life-threatening diseases. With its partners, StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies and has the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world. The company operates one of two, and the only commercial cord blood bank in the world, dually accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). StemCyte is the only private company contracted by the Federal Government to establish a National Cord Blood Inventory. For more information, visit

SOURCE StemCyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. StemCyte, Inc. Ranked Number Six in Deloittes Technology Fast 50 Program for Los Angeles
2. Rutgers research partner Stemcyte, Inc., expands to New Jersey
3. Spiritual Healer/Psychic-Medium Reaches International Status!
4. EMBL reaches north
5. AK Steel Reaches VEBA Health Care Settlement With Middletown Works Retirees
6. Sun Safety Awareness Reaches New Heights at Plano Hot Air Balloon Festival
7. 40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode
8. Blue Cross of California Reaches Out to Members Impacted by Southern California Fires
9. Free Site Offering Patient-Physician Dialog Reaches Milestone
10. Sharp HealthCare Foundation Reaches $50 Million Goal
11. Nyer Medical Group Reaches Agreement to Acquire Minority Interest in Pharmacy Chain Subsidiary
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms of ... and dry skin. But many people who find their cholesterol levels and weight are ... their thyroid, especially if they don’t have any of the other symptoms. , Thyroid ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion Bootie ... an early celebration of the early holiday shopping season. Starting Wednesday November 25th, ... $33.95 ea). Black Friday promotional pricing is in addition to any automatic discounts ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to offer their patients the many benefits of the revolutionary BIOLASE WaterLase iPlus ... cutting and scraping tools traditionally used by a dentist in Gettysburg, PA ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
(Date:11/25/2015)... 2015 Endo International plc (NASDAQ: ENDP ) ... President and CEO, will discuss corporate updates at the 27 ... New York on Wednesday, December 2, 2015 at ... Investor Relations, and then the link to the event. Participants ... time to visit the site and download any streaming media ...
Breaking Medicine Technology: